1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Looking Beyond CNS, SK Biopharm Begins First US Oncology Trial

Aims To Double Business This Year

 
• By Jung Won Shin

The CNS-focused SK Group affiliate has set out ambitious growth plans for this year and is moving forward with a diversification into oncology and other areas, beginning its first US cancer trials in brain tumors and cancers with brain metastasis.

Jeong Woo Cho, CEO Of SK Biopharmaceuticals
M&A Also On The Table To Accelerate Product Launches • Source: SK Biopharmaceuticals Co. Ltd.

With its flagship drug cenobamate settling in comfortably in the US market and its next-generation central nervous system (CNS) pipeline assets progressing smoothly through clinical trials, SK Biopharmaceuticals Co., Ltd is now expanding its realm to oncology, RNA and digital therapeutics, with ambitions to grow into a global healthcare enterprise.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia